What Stimuliver does

Stimuliver is a pre-clinical biotechnology company developing a first-in-class, vascularized, and immunomodulatory 3D liver tissue implant intended to treat acute and chronic liver disease. Founded by University of Edinburgh researchers David Hay (CEO) and Dagmara Szkolnicka (CSO), the company is a spinout from Edinburgh Innovations and is incubated at the BioInnovation Institute (BII) in Copenhagen, Denmark. Its core technology differentiates human pluripotent stem cells into hepatic progenitors and endothelial cells, combines them into spheres, and scales the tissue through an automated platform for subcutaneous implantation that bypasses the inflamed abdomen characteristic of liver patients.

The lead product is a subcutaneous liver tissue implant positioned as an off-the-shelf, renewable regenerative therapy that does not depend on donor organ availability. The platform has demonstrated vascularization to the host system within days of implantation and long-term host liver support in rodent models. Stimuliver also produces 3D liver spheroids as a research-grade product for basic and applied research. Four patent applications have been filed by the founding team in the area of stem cell differentiation toward liver tissue.

Stimuliver is pre-revenue and pre-commercial; the planned revenue model is one-time product licensing/sales to healthcare providers and transplant centers following regulatory approval. The company is financed by BioInnovation Institute (EUR 500k convertible loan), Vaekstfonden (DKK 15m co-investor in the 2022 seed), Old College Capital (undisclosed 2023 round), and Innovation Fund Denmark (DKK 2.4m Innobooster grant in 2023). A Scientific Advisory Board drawn from King's College London, MIT, the University of Edinburgh, and Verigraft provides translational and clinical guidance.

Name

Stimuliver

Legal name

Stimuliver ApS

Website

https://stimuliver.bio

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Stimuliver is a pre-clinical biotech developing a first-in-class subcutaneous 3D liver tissue implant using pluripotent stem cells, offering an off-the-shelf regenerative alternative to donor-organ transplants for acute and chronic liver disease patients.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

• Regenerative medicine
• Liver tissue implants
• Stem cell therapy
• Tissue engineering
• Biotech therapeutics

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Liver Tissue Implant Commercialization: Pre-revenue stage. The company is developing an off-the-shelf regenerative medicine product—a liver tissue implant for treating acute and chronic liver diseases. Revenue will be generated through product sales to healthcare providers once regulatory approval is obtained.

Go-to-market motion1 record

Marketing channels4 records

Core offering

Stimuliver is a pre-clinical biotechnology company developing a vascularized and immunomodulatory liver tissue implant from human pluripotent stem cells. The implant uses hepatic progenitors and endothelial cells combined into spheres, produced through an automated platform, and delivered subcutaneously to filter toxins and supplement failing liver function as an off-the-shelf regenerative treatment for acute and chronic liver diseases.

Product overview

Stimuliver is a regenerative medicine company developing a single integrated product portfolio centered on its liver tissue implant technology. The core offering is a first-in-class vascularized and immunomodulatory liver tissue implant that uses pluripotent stem cells differentiated into liver tissue, delivered via a subcutaneous remote implant. The technology consists of three interconnected components: the liver tissue implant (core therapeutic product), the remote implant technology (delivery mechanism), and 3D liver spheroids (research-grade product). All offerings are built on the same platform technology of differentiating pluripotent stem cells into viable liver tissue for scalable, off-the-shelf treatment of liver diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Liver Tissue Implant A first-in-class vascularized and immunomodulatory liver tissue implant for treating acute and chronic liver diseases. Human pluripotent stem cells are differentiated into hepatic progenitors and endothelial cells, combined into spheres, scaled through an automated platform, and implanted subcutaneously to filter toxins and support failing liver function. Designed for healthcare providers managing severe liver disease patients.
• 3D Liver Spheroids Human liver spheroids produced through an automated platform from pluripotent stem cells for use in basic and applied liver research. Targeted at researchers and pharma applications requiring cost-effective human liver tissue models.

Quantifiable outcome

• Vascularization to host system within few days
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Edinburgh Innovations (University of Edinburgh)coreStrategic or Co-development Partner · 28 May 2022Stimuliver is a spinout from Edinburgh Innovations, the University of Edinburgh's commercialisation service. The company's technology originates from world-leading research at the University of Edinburgh in liver tissue engineering.
• Scientific Advisory Board MemberscoreStrategic or Co-development Partner · 1 January 2019Stimuliver's Scientific Advisory Board includes Prof. Fiona Watt (King's College London), Prof. Linda Griffith (MIT), Prof. Giovanna Lombardi (King's College London), Dr. Petter Björquist (Verigraft), Prof. Jonathan Fallowfield (University of Edinburgh), and Mr. Ian Currie (University of Edinburgh). The board guides development of the liver implant technology.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• Organovo: Pioneer in 3D bioprinted human tissues including liver tissue for therapeutic and research applications; later pivoted to drug discovery. Comparable 3D liver tissue engineering focus.
• Aspect Biosystems: Develops bioprinted tissue therapeutics using stem-cell-derived cells and microfluidic 3D bioprinting. Comparable platform approach combining automation, stem cells, and tissue engineering.
• LyGenesis: Develops a tissue-engineering platform that grows ectopic organs (including livers) inside lymph nodes using patient hepatocytes — alternative regenerative medicine approach for liver failure directly comparable to Stimuliver's off-the-shelf liver tissue strategy.
• eGenesis: Develops engineered xenotransplant organs including genetically-modified pig livers for patients with liver failure. Competes with Stimuliver as an alternative donor-independent liver replacement strategy.
• Sigilon Therapeutics: Develops cell-encapsulation therapies for chronic diseases using engineered cells. Comparable cell-based therapeutic platform targeting organ-level dysfunction.
• Promethera Biosciences (now Cytonet): Developed cell-based therapies for liver disease, including hepatic progenitor cell infusions for ACLF and pediatric metabolic disorders. Comparable regenerative medicine approach to liver failure.

Regional players

• CytoSorbents: Commercializes extracorporeal blood-purification devices used as supportive care in liver failure and critical illness. Comparable liver-failure therapeutic category though non-cell-based modality.

Broad incumbents

• Humacyte: Commercial-stage tissue engineering company using human cells to grow bioengineered vessels and tissues at scale. Most direct publicly-traded peer in tissue-engineered regenerative medicine.
• Vertex Pharmaceuticals (VX-880 program): Vertex's VX-880 is a stem-cell-derived islet cell therapy for type 1 diabetes — analogous cell-therapy modality (encapsulated stem-cell-derived cells) reaching clinical proof-of-concept, useful benchmark for Stimuliver's regulatory and manufacturing trajectory.
• Miromatrix Medical (United Therapeutics): Acquired by United Therapeutics, Miromatrix developed bioengineered organs and tissues including liver constructs using decellularized scaffolds — directly comparable to Stimuliver's tissue-engineered liver approach but at a much later stage with corporate backing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/stimuliver

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stimuliver